Infectious Diseases are the diseases which are caused by viruses, fungi and bacteria. Many of the microorganism are present in the body which are normally did no harm body but under certain condition this microorganism may led to cause different diseases. Asia Pacific Infectious Disease Diagnosis & Treatment Market is expected to grow at a CAGR of 7.8 % during forecasted period.
Infectious Diseases Diagnosis and Treatment Market is increasing continuously in Asia Pacific region due to rising prevalence of different infectious diseases. Tropical climate, humid weather and improper handling of waste material has led to increase the prevalence of different infectious diseases. While unavailability of treatment of different diseases may hinder the growth of the market.
Asia Pacific Infectious Disease Diagnosis & Treatment Market – Key players
Abbott Laboratories (US), Becton Dickinson & Co. (US), Alere, Inc. (US), Bio-Rad Laboratories (US), Cipla (India), Danaher Corporation (US), Glaxosmithkline (UK), IPCA Laboratories (India), Pfizer (US), Roche Diagnostics (Switzerland), Johnson And Johnson (US), Novartis International (Switzerland), Siemens Healthcare (Germany), Thermo Fisher Scientific, Inc. (US), Vertex Pharmaceuticals (US) and others
Asia Pacific Infectious Disease Diagnosis & Treatment Market – Segmentation
Asia Pacific infectious disease diagnosis & treatment market is segmented on the basis of application into AIDS, Tuberculosis (TB), Hepatitis, HPV, and others. On the basis treatment it is segmented into Antibiotics, antivirals, antifungals, anti-parasitic, alternative medicine and others. On the basis of diagnostic techniques they are immunoassays, PCR, cell cultures and other and by end user the market is segmented as hospitals, clinics, reference labs and others
Asia Pacific Infectious Disease Diagnosis & Treatment Market – Competitive Landscape
The Infectious Disease Diagnosis and Treatment Market in Asia-Pacific region is growing owing to the increasing developments of key players like Lupin, Pfizer, Abbott, Cipla, and Johnson & Johnson in this region. The key players in this market have adopted strategies of maintaining their position in the market through mergers and acquisitions, strategic tie-ups and continuous new product launches.
In April 2018, Pfizer stated the approval of Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) from U.S. Food and Drug administration (FDA). TRUMENBA, first approved Breakthrough Therapy for MenB vaccine for active immunization in children aged one to nine years.
In November 2017, Cipla, an Indian pharmaceutical company stated the approval of Q-TIB drug from World Health Organization for prevention of tuberculosis infection in people infected with HIV. This approval allowed Cipla to market the TB prevention drug globally.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1322
In October 2017, Lupin Limited, a multinational pharmaceutical company stated that LUPIN Inc., its US division acquired Symbiomix Therapeutics, LLC, a privately held company engaged in developing innovative therapies for gynecologic infections. Lupin expanded its branded women’s health specialty business with acquisition of Symbiomix and Solosec franchise.
In October 2017, Abbott, a global healthcare company announced acquisition of Alere Inc. With the acquisition, Abbott strengthened its position in in-vitro diagnostic market. This acquisition further increased the growth of infectious diseases diagnostic market in Asia Pacific region as both are key players for this market.
In May 2017, Alere Inc., a global manufacturer of point of care diagnostic test launched a rapid diagnostic test Alere Malaria Ag P.f, to detect malaria infections among asymptomatic patients. With this product launch, Alere expanded its product portfolio for malaria infection.
In February 2017, drug major Cipla stated the launch of adult Hepatitis B vaccine in Indian market. For this launch, Cipla entered into a co-exclusive agreement with Serum Institute of India Private Limited (SII) which allowed Cipla to market the vaccine for adult population and SII for children and adults.
In August 2016, Lupin announced acquisition of 21 branded drugs from Shionogi & Co., a Japanese pharmaceutical company for USD 150 million. The 21 branded drugs acquired covers therapeutic areas like central nervous system, oncology, cardiovascular and anti-infectives. With this acquisition, Lupin expanded in world’s second largest pharmaceutical market.
In September 2014, Cipla Limited declared a licensing agreement with Gilead Sciences, Inc., for developing, manufacturing and selling of hepatitis C treatment drugs Sofobuvir mono, Ledipasvir mono, combination of Ledipasvir and sofosbuvir with each other or with other active substances. With this agreement, Cipla manufactured and marketed Ledipasvir and Sofosbuvir in 91 countries including India.
Asia Pacific Infectious Disease Diagnosis & Treatment Market – Regional Analysis
On regional basis, Asia Pacific infectious disease diagnosis & treatment market is segmented into Japan, China, India, Australia, Republic of Korea and Rest of Asia-Pacific. China commands the largest market for the infectious disease diagnosis & treatment due to continuous increasing prevalence of infectious diseases. India has second largest market after China.
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/1322
Some of Major Table of Contents for “Infectious Disease Diagnosis & Treatment Market Research Report- Asia Pacific Forecast to 2023”
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312